<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292951</url>
  </required_header>
  <id_info>
    <org_study_id>HE611321</org_study_id>
    <nct_id>NCT04292951</nct_id>
  </id_info>
  <brief_title>Early Goal Directed Therapy in Cardiac Surgery</brief_title>
  <official_title>Early Goal Directed Therapy vs Standard Protocol for Hemodynamic Management in Patients Undergoing Cardiac Surgery: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early goal directed therapy (EGDT) based on information from arterial waveform derived
      cardiac output (APCO) FloTrac/EV1000 system has been proved to improve postoperative outcomes
      in patients undergoing major surgery. This system, however, has the limitation to be applied
      in open-chest surgery, especially cardiac surgery. The efficiency of FloTrac/EV1000 system to
      improve postoperative outcomes in cardiac surgery is still inconclusive.

      Hypothesis: Intraoperative management in patients undergoing cardiac surgery guided by
      FloTrac/EV1000 system, compared with conventional protocol, results in better clinical
      outcomes.

      Primary outcomes: Immediate postoperative inotropic/vasoactive drugs requirement.

      Methods: Adult patients undergoing cardiac surgery will be randomized into 2 groups: EGDT
      group managed by FloTrac/EV1000 system and Control group managed by conventional protocol.

      Outcome analyses: Compare the number of inotropic/vasoactive drugs requirement at the end of
      surgery, as well as intensive care unit (ICU) stay between both groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To compare postoperative clinical outcome in adult patients undergoing cardiac
      surgery.

      Primary outcome: Postoperative inotropic/vasoactive drugs reqirement.

      Secondary outcome: ICU stay.

      Methods: Eligible patients will be randomized to 2 groups. Both groups will be managed
      intraoperatively in the same way, except fluid and inotropic/vasoactive drugs management
      protocol. EGDT group will be managed according to information derived from FloTrac/EV1000
      system, i.e., control stroke volume variation (SVV) 10-13% and give fluid when SVV &gt; 13%,
      give inotropic to maintain cardiac index (CI) 2.5-4 L/min/m2, and give vasoactive drugs to
      maintain systemic vascular resistance index (SVRI) of 1,900-2,400 dynes-sec/cm-5/m2 . Control
      group will be managed using central venous pressure (CVP) protocol, i.e., control CVP 8-12
      mmHg and give fluid when CVP &lt; 8 mmHg, give inotropic/vasoactive drugs according to blood
      pressure and heart rate as well as clinical signs at the discretion of attending
      anesthesiologists.

      Outcome analyses: Postoperative number of inotropic/vasoactive drugs requirement as well as
      ICU stay of both groups will be compared using unpaired Student-t test or Mann-Whitney U
      test.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group GDT: fluid and inotropic/vasoactive drugs management guided by FloTrac/EV1000 Group Control: fluid and inotropic/vasoactive drugs management guided by central venous pressure (CVP), blood pressure, heart rate, and clinical signs</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The patient is anesthetized, thus unaware type of treatment. The assessor is blinded of the monitor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of inotropic/vaso active drugs requirement</measure>
    <time_frame>up to Day 1 postoperatively</time_frame>
    <description>number of inotropic/vasoactive drugs required to maintain normal blood pressure and heart rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU stay</measure>
    <time_frame>up to day 10 postoperatively</time_frame>
    <description>number of hours admitted in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate level</measure>
    <time_frame>up to Day 1 postoperatively</time_frame>
    <description>serum lactate level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine level</measure>
    <time_frame>up to day 10 postoperatively</time_frame>
    <description>serum creatinine level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Postoperative Outcome</condition>
  <condition>ICU Stay</condition>
  <arm_group>
    <arm_group_label>GDT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraoperative fluid and inotropic/vasoactive drugs management based on information from FloTrac/EV1000</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraoperative fluid and inotropic/vasoactive drugs management based on CVP, blood pressure, heart rate, and clinical signs at the discretion of attending anesthesiologists</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fluid and inotropic/vasoactive management protocol</intervention_name>
    <description>GDT protocol: keep SVV 10-13% and give fluid when SVV &gt; 13%, give inotropic to maintain CI 2.5-4 L/min/m2, give vasoactive drugs to maintain SVRI 1,900-2,400 dynes-sec/cm-5/m2 Control protocol: keep CVP 8-12 mmHG and give fluid when CVP &lt; 8 mmHg, give inotropic/vasoactive to maintain normal blood pressure and heart rate</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>GDT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-80 years old

          2. Patient has ischemic or valvular heart disease

          3. Scheduled for elective cardiac surgery

          4. New York Heart Association (NYHA) or American society of Anesthesiology (ASA)
             classification I-III

          5. Body mass index (BMI) 18-24 kg/m2

          6. Provided informed consent before surgery

        Exclusion Criteria:

          1. Scheduled for emergency or redo surgery

          2. Difficulty (or contraindication to) placing a central venous catheter

          3. Inability to cooperate (e.g. mental disorder, disturbance of consciousness, mental
             retardation)

          4. Presence of blood-borne infectious disease (e.g. syphilis, acquired immunodeficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thepakorn Sathitkarnmanee, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thepakorn Sathitkarnmanee, MD</last_name>
    <phone>66-81-9547622</phone>
    <email>thepakorns@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine, Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thepakorn Sathitkarnmanee, MD</last_name>
      <phone>+66819547622</phone>
      <email>thepakorns@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sirirat Tribuddharat, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <results_reference>
    <citation>Bednarczyk JM, Fridfinnson JA, Kumar A, Blanchard L, Rabbani R, Bell D, Funk D, Turgeon AF, Abou-Setta AM, Zarychanski R. Incorporating Dynamic Assessment of Fluid Responsiveness Into Goal-Directed Therapy: A Systematic Review and Meta-Analysis. Crit Care Med. 2017 Sep;45(9):1538-1545. doi: 10.1097/CCM.0000000000002554. Review.</citation>
    <PMID>28817481</PMID>
  </results_reference>
  <results_reference>
    <citation>Kapoor PM, Kakani M, Chowdhury U, Choudhury M, Lakshmy, Kiran U. Early goal-directed therapy in moderate to high-risk cardiac surgery patients. Ann Card Anaesth. 2008 Jan-Jun;11(1):27-34.</citation>
    <PMID>18182756</PMID>
  </results_reference>
  <results_reference>
    <citation>Kusaka Y, Ohchi F, Minami T. Evaluation of the Fourth-Generation FloTrac/Vigileo System in Comparison With the Intermittent Bolus Thermodilution Method in Patients Undergoing Cardiac Surgery. J Cardiothorac Vasc Anesth. 2019 Apr;33(4):953-960. doi: 10.1053/j.jvca.2018.06.017. Epub 2018 Jun 28.</citation>
    <PMID>30077561</PMID>
  </results_reference>
  <results_reference>
    <citation>Lopes MR, Oliveira MA, Pereira VO, Lemos IP, Auler JO Jr, Michard F. Goal-directed fluid management based on pulse pressure variation monitoring during high-risk surgery: a pilot randomized controlled trial. Crit Care. 2007;11(5):R100.</citation>
    <PMID>17822565</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 1, 2020</study_first_submitted>
  <study_first_submitted_qc>March 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Thepakorn Sathitkarnmanee</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Postoperative outcome</keyword>
  <keyword>Goal directed therapy</keyword>
  <keyword>Arterial pressure derived cardiac output</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

